Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.

Norman, B H; Dantzig, A H; Kroin, J S; Law, K L; Tabas, L B; Shepard, R L; Palkowitz, A D; Hauser, K L; Winter, M A; Sluka, J P; Starling, J J

Norman, B H; Dantzig, A H; Kroin, J S; Law, K L; Tabas, L B; Shepard, R L; Palkowitz, A D; Hauser, K L; Winter, M A; Sluka, J P; Starling, J J.

Norman BH; Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

Bioorg Med Chem Lett ; 9(23): 3381-6, 1999 Dec 06.

Article en En | MEDLINE | ID: mdl-10612603

ABSTRACT

ABSTRACT

The benzothiophene LY329146 reverses the drug resistance phenotype in multidrug resistance protein (MRP1)-overexpressing cells when dosed in combination with MRP1-associated oncolytics doxorubicin and vincristine. Additionally, LY329146 inhibited MRP1-mediated uptake of the MRP1 substrate LTC4 into membrane vesicles prepared from MRP1-overexpressing cells.

Asunto(s)

Transportadoras de Casetes de Unión a ATP/antagonistas & inhibidores; Resistencia a Múltiples Medicamentos/genética; Sulfonamidas/farmacología; Tiofenos/farmacología; Antineoplásicos/farmacología; Transporte Biológico; Membrana Celular/metabolismo; Células HL-60; Células HeLa; Humanos; Leucotrieno C4/antagonistas & inhibidores; Leucotrieno C4/metabolismo; Proteínas Asociadas a Resistencia a Múltiples Medicamentos

Search on Google

Imprimir

XML

PubMed Links

Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Tiofenos / Resistencia a Múltiples Medicamentos / Transportadoras de Casetes de Unión a ATP Límite: Humans Idioma: En Año: 1999 Tipo del documento: Article

Search on Google

Imprimir

XML

PubMed Links